Ongoing Trials
Are you a healthy female aged 18-45?
- What is this all about?
Although current drugs used to treat for HCMV are effective, the drugs are also toxic at higher doses and may affect kidney and bone marrow function in some patients. The sponsor company for this study is developing a new drug called Letermovir and it is anticipated that it will be less toxic than current treatments. Letermovir may interact with other drugs such as Digoxin (Lanoxin®) which may also be given to severely ill patients (for example those suffering from heart disease) and increase its levels in the blood which may cause toxic side effects.
The aim of this part of the clinical trial is to investigate the levels of Letermovir in the blood following single and multiple intravenous doses given to healthy volunteers, as well as comparing this with levels found after taking oral doses of Letermovir, to determine suitable doses that can be given to patients intravenously to prevent or to treat HCMV infection.
The trial is being conducted at Richmond Pharmacology Ltd only.
- Who is suitable for this study?
To qualify for participation you need to:
- Be a healthy female of any ethnic origin (a minimum of 70% will be Caucasian indigenous to Europe for each cohort) aged between 18 and 45 years (inclusive) at screening
- Have a body mass index (BMI) between ≥18.0 and ≤28.0 kg/m2 (inclusive) at screening, and a body weight of at least 60 kg.
- Have a negative pregnancy test at screening and on Day -1.
- Be able to communicate well with the Investigator in English, and to understand and fully comply with the requirements of the trial.
- If you are a smoker, you must not have smoked more than 10 cigarettes or
equivalent amount of tobacco per day at screening or during the
screening period.
- Agree to use acceptable methods of contraception.
Female volunteers of childbearing potential must use medically acceptable methods of contraception (non-hormonal methods) from 4 weeks before first admission until three months following administration of the last dose of trial medication.
Acceptable methods include:
- A documented placement of an intrauterine device (IUD) or intrauterine system (IUS) and the use of a barrier method {condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository};
- Documented tubal ligation (female sterilisation). In addition, a barrier method {condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository} should also be used;
- Double barrier method: Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
- What will happen?
This study is being conducted at our research facility at Croydon University Hospital in London. If you are interested in taking part you will need to contact us to register your interest.
If you successfully pass the telephone screening you will be invited to our facility where you will undergo a screening examination. This is vital to ensure it is safe for you to take part in the trial. You will be required to attend a screening visit 2 to 21 days before the start of the study. If you pass the screening visit you will be invited to take part in the study.
PART B
Participation for this part of the trial requires you to stay at our clinical unit at Croydon University Hospital for 2 residential trial periods, the first lasting for 6 days (Visit 2) and the second lasting for 12 days (Visit 3) and then a follow up period 7-14 days (Visit 4) after you are discharged from the unit. Your participation in this study will last approximately 48 days including the screening visit (Visit 1) within 2-21 days before the first dose of the study drug.
Study dates for this part of the trial are as follows:
Group 3
Visit 1:
Admissions: 29/05/2012
Dismissal: 03/06/2012
Visit 2:
Admissions: 05/06/2012
Dismissal: 16/06/2012
Follow up: 25/06/2012
- What’s in it for you?
You will receive £1,250 your time on completion of the study, once follow-up results are confirmed, checked and deemed complete by the study doctor. You will be paid an additional bonus of £630 subject to your satisfactory compliance with the documents provided before study commencement (Volunteer Information sheet and Informed Consent, the Richmond Pharmacology Volunteer Charter and all other unit regulations).
The total amount that you could be paid for participation is £1,880. This payment includes all travel expenses.
- Want to find out more?
Or
Call us free on +44 (0) 20 8664 5200 (select option 1) and speak to a member of our Volunteer Recruitment Team.
A detailed information sheet is available on request.
Ref: AC 1_Sep 2011 (PART B)
11061_eDM and web story_version 2.0_PART B_29 03 12_clean.docx
Register now for more details!
Do you suffer from diabetes and diabetes-related pain in the lower limbs?
Have you ever wondered how new pharmaceutical products are researched?
We invite you to be part of this development process
You will receive payment for your participation to reimburse you for your time and inconvenience.
- Who we are
Richmond Pharmacology conducts medical research to help develop new medicines. Our 2 research units are based in London at St George’s University Hospital and Croydon University Hospital. Richmond Pharmacology works with Hospital Consultants, Research Physicians, and Clinicians. This study is sponsored by Abbott and has been approved by an independent research ethics committee.
- What is this all about?
The trial is being conducted at Richmond Pharmacology only.
If you take part in the study, you will receive either:
- Oral ABT-639 and placebo (dummy drug) infusion;
- Lidocaine* infusion (which is also used to treat neuropathic pain. In this study it will be used as a comparator to see how well the ABT-639 is working) and oral placebo (dummy drug);
- Placebo (dummy drug) infusion and oral placebo (dummy drug).
* Lidocaine is a local anaesthetic injected through the skin which you may be familiar with from dental treatments or other conditions requiring numbness of pain. Intravenous Lidocaine is also used to treat pain such as the neuropathic pain that you have. The doses you will receive are similar to dose regimens used in pain clinics.
- Who is suitable for this study?
To qualify for participation in this study you must:
Be able to communicate well with the Investigator in English, and to understand and fully
comply with the requirements of the trial.
Be aged between 18 and 75 years (inclusive) at screening
Have a documented diagnosis of diabetes mellitus type 1 or type 2
Have presence of diabetes-related pain in the lower limbs of the body
Have a body mass index (BMI) between ≥18.5 and ≤33.0 kg/m2 (inclusive). Your BMI is
calculated using the formula: weight (in kilograms) divided by height (in metres) squared).
If you are female, have a negative pregnancy test at screening and on Day -1.
Females of child-bearing potential must be using an adequate and medically acceptable
method of contraception;
Acceptable methods include:
- Use an effective method of birth control (e.g., oral contraceptives or intrauterine device combined with a double-barrier method [e.g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel], or male partner sterilisation) before enrolment until 90 days after your last dose. All patients, whether they complete the study or not, will be requested to use an effective method of birth control for 90 days after their last dose
- Be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation or otherwise be incapable of pregnancy)
- Be abstinent when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- Male patients must agree not to donate sperm, and to take appropriate precautions to avoid fathering a child, throughout the study and until 90 days after the end of treatment.
- Other restrictions and exclusions apply – please ask for details.
- What will happen?
This study is being conducted at our research facility at Croydon University Hospital in London. If you are interested in taking part you will need to contact us to register your interest.
If you successfully pass the telephone screening you will be invited to our facility where you will undergo a screening examination. This is vital to ensure you are eligible to take part in the trial. You will be required to attend two screening visits 30 days before the start of the study. If you pass the screening visit you will be invited to take part in the study.
- Study Participation
Participation for this study requires you to attend up to 2 out-patient visits and one residential stay of 1 night and 2 days at our clinical unit at Croydon University Hospital. Your participation in this study will last approximately 35 days. This includes the two screening visits (Visit 1 and Visit 2) within 30 days before the start of the study, one residential stay of 1 night/2 days at our unit (Visit 3) and a final follow up telephone call 3 days after the last dose of the study drug.
- What’s in it for you?
Apart from helping medical research, we will also compensate you for your time and inconvenience in the form of a monetary payment. You will receive up to £460 for your time on completion of the study.
- What are the possible side effects?
ABT-639 has previously been given to both healthy volunteers and patients. To date, the most common side effects are headaches, frequent urination, dizziness, diarrhoea, feeling tired, stomach ache, passing gas, feeling faint, pinkeye, stomach growling, redness and swelling of the inside of the nose, sleepiness, feeling restless, and redness, pain and swelling at the site of blood sampling or ECG (electrical heart recording) tabs.
Lidocaine is a widely used drug and so we understand the side effects much better. Side effects of Lidocaine at higher levels than expected to be used in this study include lightheadedness, oral numbness or tingling, dizziness, hearing disturbances, dysarthria (speech disorders), increased blood pressure, nausea and headache. At very high doses, more serious side-effects including seizures (convulsions) and cardiac arrest can occur but we will not be giving such high levels so only minor side-effects may occur, if any. It is unlikely that any serious side-effects will occur; however,an anaesthetist who is familiar with the administration of Lidocaine and treatment of its side effects will be present throughout the Lidocaine infusion period and at least one hour after infusion completed.
As for all drugs during development, it is not possible to predict all side effects. All drugs may cause unforeseen complications that have not been previously reported.
- Want to find out more?
If you are interested in finding out more please send your full name, contact telephone number and email address to diabetes@richmondpharmacology.com
Or
Call us on 020 8664 5200 (select option 1) and speak to a member of our Volunteer Recruitment Team.
A detailed information sheet is available on request.
Ref: ABT_DEC 2011
The contents of this email/web page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.
No deductions will be made for Tax and insurance, it will be your own responsibility to report the payment to the relevant authorities.
If you are in receipt of any benefits, the payment you receive for taking part in this study may affect your eligibility to those benefits.
On occasion, we are required by law to disclose such payments when requested.
You may be required to remain resident in the unit until resolution of any safety issues,
after which you will be discharged from the unit.
Advert version number and date: C11069_eDM and web story_version 4 0_12 04 12_clean.docx
Register now for more details!
Take part in a trial this April and earn up to £1,480 for your time
- What is this all about?
Osteoarthritis is a disease that affects the joints of the body, typically the knees, the hips, and the fingers. It is the most common joint disorder throughout the world, and it very often leads to disability in elderly people. Sufferers of osteoarthritis experience pain and stiffness in their joints and are less able to move around.
Currently, one of the drugs available to treat pain in patients with osteoarthritis is Diclofenac. Diclofenac belongs to the group of drugs called NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). It has a strong painkiller action but the effect is short-lasting and so to maintain its effect it needs to be taken repeatedly. Diclofenac taken repeatedly for long periods of time can have considerable side effects since it is absorbed into the bloodstream. It can affect other parts of the body, such as the stomach, kidneys and airways.
SI-613 (the study drug) is a new combination of two well known drugs, diclofenac and hyaluronic acid to be used as in the form of a knee injection for treatment of Osteoarthritis. Both drugs are linked together chemically to create a new compound, which is expected to exert a strong and long-lasting pain relief. Since the Diclofenac will be given into the knee it will be less likely to enter the bloodstream and cause side effects.
In this study, we will be testing SI-613 which will be delivered as a one-off injection into the knee. This new drug combination has never been tested in humans before, and so the main purpose of the study is to see how this new drug combination is handled by both healthy Caucasian and Japanese males and whether there are any side effects.
The trial is being conducted at Richmond Pharmacology Ltd only.
- Who is suitable for this study?
To qualify for participation you need to:
- Be a healthy Caucasian or Japanese male, aged 20 - 40 years old (inclusive)
- Caucasian volunteers: you have white to light brown skin pigmentation and straight to wavy or curly hair, and you are from Europe or Northern Africa. Therefore, the study may include Caucasian volunteers from North America, Australia and South Africa.
- Japanese volunteers: Both of your parents and all four grandparents must be Japanese, you must carry a Japanese passport and you should usually reside in Japan but can have been resident outside of Japan for up to 5 years
- Have a body mass index (BMI) between ≥18.5 and ≤25.0 kg/m2 (inclusive) at screening, and a body weight of at least 50 kg. Your BMI is calculated using the formula: weight (in kilograms) divided by height (in metres) squared.
- You are in good health as determined by physical examination, knee examination and laboratory blood tests.
- You must be willing to use accepted contraceptive methods, avoid unprotected sex, and donating sperm until 3 months after treatment.
- You are able to provide written consent, communicate and are able to understand and be willing to comply with study procedures, restrictions and requirements.
- What will happen?
This study is being conducted at our research facility at Croydon University Hospital in London. If you are interested in taking part you will need to contact us to register your interest.
If you successfully pass the telephone screening you will be invited to our facility where you will undergo a screening examination. This is vital to ensure it is safe for you to take part in the trial. You will be required to attend a screening visit 2 to 21 days before the start of the study. If you pass the screening visit you will be invited to take part in the study.
- Study Participation
- What’s in it for you?
You will receive £990 your time on completion of the study, once follow-up results are confirmed, checked and deemed complete by the study doctor. You will be paid an additional bonus of £490 subject to your satisfactory compliance with the documents provided before study commencement (Volunteer Information sheet and Informed Consent, the Richmond Pharmacology Volunteer Charter and all other unit regulations).
The total amount that you could be paid for participation is £1,480. This payment includes all travel expenses.
- Want to find out more?
If you are interested in finding out more Click
here to register
Or
Call us free on 020 8664 5200 (select option 1) and speak to a member of our Volunteer Recruitment Team.
A
detailed information sheet is available on request.
Ref: SK 1_Oct 2011
The contents of this email/web page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.
No deductions will be made for Tax and insurance, it will be your own responsibility to report the payment to the relevant authorities.
If you are in receipt of any benefits, the payment you receive for taking part in this study may affect your eligibility to those benefits.
On occasion, we are required by law to disclose such payments when requested.
You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.
C10050_eDM and web story_version 5.0_22 12 2011_ clean.doc
Register now for more details!
Do you suffer from chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), psoriasis or asthma?
Have you ever wondered how new pharmaceutical products reach the market?
Would you like to be part of that development process and do something good today?
You will even receive payment for the time you give us during your participation.
- Who we are
Richmond Pharmacology conducts medical research to help develop new medicines. Our 2 research units, based in London at St George’s University Hospital and Croydon University Hospital, provide you with the safest and most comfortable facilities. Richmond Pharmacology works closely with Hospital Consultants, Research Physicians, and Clinicians ensuring the research we conduct is meaningful, ethical, and safe.
- What is this all about?
Chronic inflammation is most appropriately defined in terms of the process, in which continuing inflammation and attempted tissue healing by repair occur simultaneously. Chronic inflammation results in a variety of diseases, depending on the location of and trigger for the inflammation. These diseases include asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA) and psoriasis but there are many other diseases and disorders caused by chronic inflammation.
Richmond Pharmacology is conducting a clinical trial for a new experimental drug called FX125L. FX125L is an anti-inflammatory agent being developed for the treatment of chronic inflammatory diseases such as asthma, COPD, RA and psoriasis. It is anticipated that FX125L may be more effective and have fewer side effects compared to the current marketed drugs.
This is the first time FX125L will be given to patients with chronic inflammation. The purpose of this study, therefore, is to examine the impact of treatment with such an agent in patients with a range of different diseases that share a chronic inflammatory component. The purpose of this study is also to collect information on markers which will help us to plan future research studies, to further test the effect of this compound.
The trial is being conducted at Richmond Pharmacology Ltd only.
- Who is suitable for this study?
To qualify for participation you need to:
- Be aged between 18 and 77 years (inclusive) at screening
- Have a documented diagnosis of one of the following four conditions: asthma, COPD, RA or psoriasis (with a confirmed medical history available from your GP).
- Have a body mass index (BMI) between ≥18.0 and ≤35.0 kg/m2 (inclusive). Your BMI is calculated using the formula: weight (in kilograms) divided by height (in metres) squared).
- If you are female, have a negative pregnancy test at screening and on Day -1.
- Females of child-bearing potential must be using an adequate and medically acceptable method of contraception;
Acceptable methods include:
- Use an effective method of birth control (e.g., oral contraceptives combined with another method of birth control, intrauterine device, double-barrier method [e.g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel], or male partner sterilisation) before enrolment until the follow-up visit. All patients, whether they complete the study or not, will be requested to use an effective method of birth control for 90 days after their last dose
- Be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation or otherwise be incapable of pregnancy)
- Be abstinent when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception, or
- Be postmenopausal (for at least 1 year); post-menopausal patients with FSH ≤40 mIU/mL must use an effective method of birth control
- Male patients must agree not to donate sperm, and to take appropriate precautions to avoid fathering a child, throughout the study and until 90 days after the end of treatment.
- What will happen?
This study is being conducted at our research facility at Croydon University Hospital in London. If you are interested in taking part you will need to contact us to register your interest.
If you successfully pass the telephone screening you will be invited to our facility where you will undergo a screening examination. This is vital to ensure it is safe for you to take part in the trial. You will be required to attend a screening visit 14 to 28 days before the start of the study. If you pass the screening visit you will be invited to take part in the study.
- Study Participation
- What’s in it for you?
Apart from doing something good, we will also compensate you for your time in the form of a monetary payment.
You will receive £560 your time on completion of the study, once follow-up results are confirmed, checked and deemed complete by the study doctor. You will be paid an additional bonus of £280 subject to your satisfactory compliance with the documents provided before study commencement (Volunteer Information sheet and Informed Consent, the Richmond Pharmacology Volunteer Charter and all other unit regulations).
The total amount that you could be paid for study participation is £840. You will also be compensated for your travel expenses.*
* You will receive travel expenses up to a value of £150 if you are included in the study and following the delivery of valid receipts for travel relating to your participation in this study. All study related travel expenses within the limit of £150 will be paid in conjunction with your study payment following the completion of your participation in the trial.
- Want to find out more?
Or
Call us free on 0800 085 64 64 and speak to a member of our Volunteer Recruitment Team.
A detailed information sheet is available on request.
Ref: FXT_Oct 2011
C11067_eDM and web story_version 1_24 10 11.docx
Register now for more details!
Recommend a Friend
If you are not selected to take part in a study you could still earn money. Recommend a friend successfully to take part in this study, and once they have completed the study you could earn anything from £90 to £350!
Register now for more details!
Please upgrade
your Flash Player
St George's and Mayday Hospitals
could earn between £90 - £350
also receive £5 for travel expenses
Please upgrade
your Flash Player
